Clinical trial
Do HMG CoA Reductase Inhibitors Affect Abeta Levels?
NCT00303277 · Seattle Institute for Biomedical and Clinical Research, Other · Completed
Key facts
| NCT number | NCT00303277 |
|---|---|
| Title | Do HMG CoA Reductase Inhibitors Affect Abeta Levels? |
| Official title | Do HMG CoA Reductase Inhibitors Affect Abeta Levels? |
| Lead sponsor | Seattle Institute for Biomedical and Clinical Research, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease, Aging |
| Intervention type | Drug |
| Interventions | simvastatin, pravastatin |
| Enrollment | 35 |
| Start date | Aug 1, 2002 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Mar 16, 2006 |
| Last update posted | Apr 13, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: